These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38153320)

  • 1. Long-Term Safety and Efficacy of Initial and Repeat Treatment Courses With Zuranolone in Adult Patients With Major Depressive Disorder: Interim Results From the Open-Label, Phase 3 SHORELINE Study.
    Cutler AJ; Mattingly GW; Kornstein SG; Aaronson ST; Lasser R; Zhang H; Rana N; Brown C; Levin S; Miller C; Kotecha M; Forrestal F; Doherty J
    J Clin Psychiatry; 2023 Dec; 85(1):. PubMed ID: 38153320
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study.
    Parikh SV; Aaronson ST; Mathew SJ; Alva G; DeBattista C; Kanes S; Lasser R; Bullock A; Kotecha M; Jung J; Forrestal F; Jonas J; Vera T; Leclair B; Doherty J
    Neuropsychopharmacology; 2024 Jan; 49(2):467-475. PubMed ID: 37875578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial.
    Deligiannidis KM; Meltzer-Brody S; Gunduz-Bruce H; Doherty J; Jonas J; Li S; Sankoh AJ; Silber C; Campbell AD; Werneburg B; Kanes SJ; Lasser R
    JAMA Psychiatry; 2021 Sep; 78(9):951-959. PubMed ID: 34190962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zuranolone in Major Depressive Disorder: Results From MOUNTAIN-A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
    Clayton AH; Lasser R; Nandy I; Sankoh AJ; Jonas J; Kanes SJ
    J Clin Psychiatry; 2023 Feb; 84(2):. PubMed ID: 36811520
    [No Abstract]   [Full Text] [Related]  

  • 5. The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials.
    Clayton AH; Suthoff E; Jain R; Kosinski M; Fridman M; Deligiannidis KM; Meltzer-Brody S; Chen SY; Gervitz L; Huang MY; Trivedi M; Bonthapally V
    J Affect Disord; 2024 Apr; 351():904-914. PubMed ID: 38325605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, phase 2 clinical trial.
    Kato M; Nakagome K; Baba T; Sonoyama T; Okutsu D; Yamanaka H; Shimizu R; Motomiya T; Inoue T
    Psychiatry Clin Neurosci; 2023 Sep; 77(9):497-509. PubMed ID: 37252829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial.
    Clayton AH; Lasser R; Parikh SV; Iosifescu DV; Jung J; Kotecha M; Forrestal F; Jonas J; Kanes SJ; Doherty J
    Am J Psychiatry; 2023 Sep; 180(9):676-684. PubMed ID: 37132201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of zuranolone for the treatment of depression: A systematic review and meta-analysis.
    Li Z; Wu Q; Peng P; Wu M; Liu S; Liu T
    Psychiatry Res; 2024 Jan; 331():115640. PubMed ID: 38029628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zuranolone for the Treatment of Postpartum Depression.
    Deligiannidis KM; Meltzer-Brody S; Maximos B; Peeper EQ; Freeman M; Lasser R; Bullock A; Kotecha M; Li S; Forrestal F; Rana N; Garcia M; Leclair B; Doherty J
    Am J Psychiatry; 2023 Sep; 180(9):668-675. PubMed ID: 37491938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zuranolone and its role in treating major depressive disorder: a narrative review.
    Ali M; Ullah I; Diwan MN; Aamir A; Awan HA; Waris Durrani A; Qudrat QU; Shoib S; De Berardis D
    Horm Mol Biol Clin Investig; 2023 Jun; 44(2):229-236. PubMed ID: 36848317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder.
    Meshkat S; Teopiz KM; Di Vincenzo JD; Bailey JB; Rosenblat JD; Ho RC; Rhee TG; Ceban F; Kwan ATH; Cao B; McIntyre RS
    J Affect Disord; 2023 Nov; 340():893-898. PubMed ID: 37557991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression.
    Deligiannidis KM; Citrome L; Huang MY; Acaster S; Fridman M; Bonthapally V; Lasser R; Kanes SJ
    J Clin Psychiatry; 2023 Jan; 84(1):. PubMed ID: 36724109
    [No Abstract]   [Full Text] [Related]  

  • 15. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the safety and efficacy of zuranolone in the management of major depressive disorder and postpartum depression, with or without concurrent insomnia: a rigorous systematic review and meta-analysis.
    Raja A; Ahmed S; Basit Ali Siddiqui M; Lamiya Mir S; Kumar R; Ahmed M; Raja S; Bin Amin S; Alim Ur Rahman H; Deepak F; Asghar MS
    Front Psychiatry; 2024; 15():1425295. PubMed ID: 39035602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zuranolone for treatment of major depressive disorder: a systematic review and meta-analysis.
    Ahmad A; Awan AR; Nadeem N; Javed AS; Farooqi M; Daniyal M; Mumtaz H
    Front Neurosci; 2024; 18():1361692. PubMed ID: 38726035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder.
    Suthoff E; Kosinski M; Arnaud A; Hodgkins P; Gunduz-Bruce H; Lasser R; Silber C; Sankoh AJ; Li H; Werneburg B; Jonas J; Doherty J; Kanes SJ; Bonthapally V
    J Affect Disord; 2022 Jul; 308():19-26. PubMed ID: 35378149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zuranolone Concentrations in the Breast Milk of Healthy, Lactating Individuals: Results From a Phase 1 Open-Label Study.
    Deligiannidis KM; Bullock A; Nandy I; Dunbar J; Lasser R; Witte M; Leclair B; Wald J
    J Clin Psychopharmacol; 2024 Jul-Aug 01; 44(4):337-344. PubMed ID: 38739007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Perahia DG; Wang F; Mallinckrodt CH; Walker DJ; Detke MJ
    Eur Psychiatry; 2006 Sep; 21(6):367-78. PubMed ID: 16697153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.